A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.


Updates from The Motley Fool

Latest updates on EPIRUS Biopharmaceuticals from Fool.com.


Stock Performance

EPRS vs. S&P 500 | 2 Year Performance
View Interactive EPRS Charts
Sponsored by

Key Data Points

Primary metrics and data points about EPIRUS Biopharmaceuticals.
Current Price: $0.14
Prev Close: $0.15
Open: $0.17
Bid: $0.16
Ask: $0.16
Day's Range: $0.13 - $0.17
52wk Range: $0.08 - $6.76
Volume: 3,985,971
Avg Vol 4,735,951
Market Cap: $3.36M
P/E (ttm): -0.06
EPS (ttm): -$2.56
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about EPIRUS Biopharmaceuticals.
CAPS Rating 3 out of 5
 
263 Outperform
15 Underperform
CAPS All Stars
 
28 Outperform
2 Underperform

How do you think EPIRUS Biopharmaceuticals will perform against the market?



You pick for EPIRUS Biopharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


Business Summary

Industry, sector and description for EPIRUS Biopharmaceuticals.

A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers